Antiretroviral therapy for HIV infection - A knowledge-based approach to drug selection and use

被引:36
作者
Moyle, GJ
Gazzard, BG
Cooper, DA
Gatell, J
机构
[1] Chelsea & Westminster Hosp, Kobler Ctr, London SW10 9TH, England
[2] Natl Hlth & Med Res Council, Sydney, NSW, Australia
[3] St Vincents Hosp, Sydney, NSW 2010, Australia
[4] Hosp Clin Provencal, Barcelona, Spain
基金
英国医学研究理事会;
关键词
D O I
10.2165/00003495-199855030-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the absence of evidence that eradication of HIV from an infected individual is feasible, the established goal of antiretroviral therapy is to reduce viral load to as low as possible for as long as possible. Achieving this with the currently available antiretroviral agents involves appropriate selection of components of combination regimens to obtain an optimal antiviral response. In addition, consideration of a plan for a salvage or second-line regimen is required if initial therapy fails to achieve an optimal response or should loss of virological control occur despite effective initial therapy. Such a planned approach, based on consideration of the likely modes of therapeutic failure (viral resistance, cellular resistance, toxicity) could be called rational sequencing. Choice of therapy should never involve compromise in terms of activity. However, the choice of drug should also be guided by tolerability profiles and considerations of coverage of the widest range of infected cells, compartmental penetration, pharmacokinetic interactions and, importantly, the ability of an agent or combination to limit future therapeutic options through selection of cross-resistant virus. Available clinical end-point data clearly indicate that combination therapy is superior to monotherapy. with clinical and surrogate marker data supporting the use of triple drug (or double pretense inhibitor) combinations over double nucleoside analogue combinations. Thus. 3-drug therapy, should represent current standard practice in a nontrials setting Treatment should be considered as early as practical, and may be best guided by measurement of. viral load, with a range of other markers having potential utility in individualism treatment decisions. Therapeutic failure may be defined clinically. immunologically or, ideally, virologically, and should prompt substitution of at least 2. and preferably all, components of the treatment regimen. Drug intolerance may also be best managed by rational substitution.
引用
收藏
页码:383 / 404
页数:22
相关论文
共 167 条
[1]  
Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
[2]   A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
ABRAMS, DI ;
GOLDMAN, AI ;
LAUNER, C ;
KORVICK, JA ;
NEATON, JD ;
CRANE, LR ;
GRODESKY, M ;
WAKEFIELD, S ;
MUTH, K ;
KORNEGAY, S ;
COHN, DL ;
HARRIS, A ;
LUSKINHAWK, R ;
MARKOWITZ, N ;
SAMPSON, JH ;
THOMPSON, M ;
DEYTON, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) :657-662
[3]   Zalcitabine - An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection [J].
Adkins, JC ;
Peters, DH ;
Faulds, D .
DRUGS, 1997, 53 (06) :1054-1080
[4]  
ALLAN JD, 1993, 9 INT C AIDS 4 WORLD
[5]  
BACK DJ, 1995, 5 EUR C CLIN ASP TRE
[6]   GENOMIC VARIATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) - MOLECULAR ANALYSES OF HIV-1 IN SEQUENTIAL BLOOD-SAMPLES AND VARIOUS ORGANS OBTAINED AT AUTOPSY [J].
BALL, JK ;
HOLMES, EC ;
WHITWELL, H ;
DESSELBERGER, U .
JOURNAL OF GENERAL VIROLOGY, 1994, 75 :867-879
[7]  
BERTZ RJ, 1996, 11 INT C AIDS JUL 7
[8]  
BIRON F, 1995, J ACQ IMMUN DEF SYND, V10, P36
[9]  
BODSWORTH NJ, 1997, 7 INT ANT S FEB 17 1
[10]  
BORLEFFS JCC, 1997, 6 EUR C CLIN ASP TRE